Abstracts tagged "Psoriatic arthritis"

Abstract Number: 0543 • ACR Convergence 2025
Unveiling Sacroiliac Joint Involvement in Psoriatic Arthritis: MRI, Radiographic, and Clinical Insights from 581 European Routine Care Patients
Nora Vladimirova¹, Anna EF Hadsbjerg², Simon Krabbe³, Adrian Ciurea⁴, Kristýna Bubová⁵, Monika Gregova⁵, Michael Nissen⁶, Burkhard Moeller⁷, Raphael Micheroli⁴, Susanne Pedersen⁸, Jakub Zavada⁵, Ziga Snoj⁹, Karlo Pintaric⁹, Bjorn Gudbjornsson¹⁰, Ziga Rotar¹¹, iris Eshed¹², Iwona Iwona Sudol-Szopinska¹³, Kasper Gosvig¹⁴, Torsten Diekhoff¹⁵, Robert G. W. Lambert¹⁶, Manouk de Hooge¹⁷, Maurice Donzallaz¹⁸, Alexander Bernatschek¹⁸, Merete Hetland¹⁹, Lykke Ørnbjerg²⁰ and Mikkel Ostergaard²¹, ¹Rigshospitalet-Glostrup, Copenhagen, Denmark, ²Copenhagen Center for Arthritis Research, COPECARE, Glostrup, Denmark, ³Rigshospitalet, København, Denmark, ⁴University Hospital Zurich, Zurich, Switzerland, ⁵Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine Charles University, Prague, Czech Republic, ⁶Rheumatology Department, Geneva University Hospital, Geneva, Switzerland, ⁷Department of Rheumatology and Immunology, Inselspital, University Hospital Bern,, Bern, Swaziland, ⁸Rigshospitalet, København �, Denmark, ⁹Institute of Radiology, UMC Ljubljana,, Ljubliana, Slovenia, ¹⁰Landspitali University Hospital; Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹¹University Medical Centre Ljubljana, Ziri, Slovenia, ¹²Department of Diagnostic Imaging, Sheba Medical Center, Tel Hashomer affiliated with School of Medicine, Tel Aviv University, Tel Aviv, Israel, ¹³Department of Radiology, National Institute of Geriatrics, Rheumatology and Rehabilitation,, Warsaw, Poland, ¹⁴Department of Radiology, Copenhagen University Hospital Herlev-Gentofte,, Copenhagen, Denmark, ¹⁵Charite Universitetsmedizin Berlin, Berlin, Germany, ¹⁶University of Alberta, Department of Radiology & Diagnostic Imaging, Edmonton, AB, Canada, ¹⁷Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ¹⁸Department of Rheumatology, University Hospital of Zurich, University of Zurich,, Zurich, Switzerland, ¹⁹Copenhagen Center for Arthritis Research (COPECARE) and DANBIO, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark, ²⁰Rigshospitalet, Glostrup, Denmark, ²¹Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, and Copenhagen Center for Arthritis Research, Center for Rheumatology, Rigshospitalet, Glostrup, Denmark
Background/Purpose: Axial involvement in psoriatic arthritis (axPsA) is associated with more severe disease and greater pain compared to PsA with only peripheral disease. However, a…
Abstract Number: 0565 • ACR Convergence 2025
Combination of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: A Case-Series
Andre Lucas Ribeiro¹, Virginia Carrizo Abarza², Jensen Yeung³, Khalad Maliyar³, Siddhartha Sood³, Ahmet Bagit³, Muskaan Sachdeva³, Sahil Koppikar⁴, Dafna D. Gladman⁵, Vinod Chandran⁶ and Lihi Eder⁶, ¹Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, ²Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ³Women's College Hospital & University of Toronto, Toronto, ON, Canada, ⁴Women's College Hospital & University of Toronto, Markham, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: Despite advances in psoriatic arthritis (PsA) treatment, remission remains elusive for many patients. This has prompted growing interest in combining biologic and targeted synthetic…
Abstract Number: 0590 • ACR Convergence 2025
Effect of Deucravacitinib Treatment on Disease Activity–Associated Plasma Biomarkers in Patients With Active Psoriatic Arthritis: Results From 2 Phase 3 Studies
Vinod Chandran¹, Oliver FitzGerald², Philip J. Mease³, Lihi Eder⁴, Jose Scher⁵, Christopher Ritchlin⁶, Dafna D. Gladman⁷, Walter P Maksymowych⁸, Coryandar Gilvary⁹, Aditi Basu Bal⁹, Eleni Vritzali¹⁰ and Jinqi Liu⁹, ¹Division of Rheumatology, Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto, and Gladman Krembil Psoriatic Arthritis Research Program, Krembil Research Institute, University Health Network, Toronto, Canada, ²UCD, Dublin ⁶, Dublin, Ireland, ³Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁴University of Toronto, Toronto, ON, Canada, ⁵New York University School of Medicine, New York, NY, ⁶University of Rochester Medical Center, Canandaigua, NY, ⁷Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁸Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁹Bristol Myers Squibb, Princeton, NJ, ¹⁰Bristol Myers Squibb, Boudry, Switzerland
Background/Purpose: Understanding how treatments affect disease-relevant biomarker expression is essential for advancing targeted therapies. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, has…
Abstract Number: 1413 • ACR Convergence 2025
Restless Legs Syndrome in Patients with Psoriatic Arthritis: Association with Inflammatory, Clinical Parameters, and Comorbidities
Esther Toledano¹, Carlos Villegas², Carolina Cristina Chacón³, Cristina Hidalgo Calleja³, Belén Miguel³, Laura Blanco³, Ana Turrión⁴, Olga Compán⁵, Manuel Martín⁴, Susana Gómez³ and Carlos Montilla³, ¹Rheumatology Service, San Carlos Clinical Hospital, Madrid, Spain, ²Faculty of Medicine, University of Salamanca, Salamanca, Spain, ³Rheumatology Service, University Hospital of Salamanca, Salamanca, Castilla y Leon, Spain, ⁴Rheumatology Service, University Hospital of Salamanca, Salamanca, Spain, ⁵Rheumatology Service, University Hospital of Salamanca, Carbajosa de la Sagrada, ³⁷¹⁹¹, Spain
Background/Purpose: Restless legs syndrome (RLS) is a chronic neurological disorder associated with brain iron metabolism. Although RLS has been linked to various immune-mediated inflammatory diseases,…
Abstract Number: 1453 • ACR Convergence 2025
Real-World Comparative Effectiveness of Upadacitinib in Psoriatic Arthritis: Evaluation of Switching to Upadacitinib Versus Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors After First-Line Tumor Necrosis Factor Inhibitors
Philip J. Mease¹, William Tillett², Xiaolan Ye³, Christopher Saffore⁴, Molly Edwards⁵, Isabel Truman⁵, Sophie Barlow⁶, Jayne Stigler⁷, Bhumik Parikh⁸ and Daniel Aletaha⁹, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ³AbbVie Inc., Mettawa, IL, ⁴AbbVie Inc., waukegan, IL, ⁵Adelphi Real World, Bollington, United Kingdom, ⁶AbbVie, North Chicago, IL, ⁷AbbVie, Round Lake, IL, ⁸AbbVie, Hillsborough Township, NJ, ⁹Medical University Vienna, Wien, Austria
Background/Purpose: The aim of this study was to compare the effectiveness of switching from a first-line TNFi to upadacitinib (UPA), an oral JAKi, versus cycling…
Abstract Number: 1715 • ACR Convergence 2025
Spondyloarthritis and Psoriatic Arthritis Patients Under Immunosuppressive Conventional and Biologic DMARDs: Favorable Disease Safety and Attenuated Immunogenicity Following Recombinant Herpes Zoster Vaccination
Carla Saad¹, Eduardo Borba², Fernanda Chaer³, Ana C Medeiros-Ribeiro¹, Sandra G Pasoto¹, Nadia Emi Aikawa⁴, Luisa Correia⁵, Percival Sampaio-Barros⁶, Julio Moraes⁷, Murillo Dorio¹, Claudia Goldenstein-Schainberg¹, Clovis Artur Silva⁸ and Eloisa Bonfa², ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ²Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Santos, Brazil, ⁴Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, ⁶Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil, ⁷Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Jundiai, Brazil, ⁸University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) patients are at increased risk for herpes zoster(HZ) due to impaired cell-mediated immunity associated with the underlying…
Abstract Number: 2309 • ACR Convergence 2025
Lifestyle behaviours and disease activity in patients with psoriatic arthritis: the Dutch south west psoriatic arthritis study
Batoul Hojeij¹, Ilja Tchetverikov², Marijn Vis¹, Marc R Kok³, Yvonne Goekoop-Ruiterman⁴, Jessica Bijsterbosch⁵, Paul Baudoin⁶, Reinhard Bos⁷, Jos H van der Kaap⁸, Petra Kok⁹, Lindy-Anne Korswagen¹⁰ and Jolanda J Luime¹, ¹Erasmus MC, Rotterdam, Netherlands, ²Albert Schweitzer Hospital, Dordrecht, Netherlands, ³Maasstad Hospital, Rotterdam, Netherlands, ⁴Haga Hospital, the Hague, Netherlands, ⁵Amphia Hospital, Breda, Netherlands, ⁶Reumazorg Zuid West Nederland, Roosendaal, Netherlands, ⁷Medisch Centrum Leeuwarden, Leeuwarden, Netherlands, ⁸Admiraal De Ruyter Hospital, Goes, Netherlands, ⁹Reinier de Graaf Hospital, Delft, Netherlands, ¹⁰Franciscus Gasthuis and Vlietland, Rotterdam, Netherlands
Background/Purpose: Comprehensive assessment of multiple lifestyle behaviours and disease activity outcomes in psoriatic arthritis (PsA) is scarce. We aim to investigate lifestyle behaviours in patients…
Abstract Number: 2351 • ACR Convergence 2025
Modulation of Tyrosine Kinase 2- and Disease-Related Biomarkers by Zasocitinib (TAK-279), an Oral, Allosteric, Highly Selective and Potent Tyrosine Kinase 2 Inhibitor, Is Associated With Clinical Response in Patients with Active Psoriatic Arthritis
Amit Choudhury¹, Jie Cheng², Feng Hong¹, Sachin Kumar¹, Jay Tang¹, Paresh Thakker¹, Banishree Saha¹, Vinayagam Arunachalam³, Ting Hong³, Elena Tomaselli Muensterman¹, Haakan Wennbo³ and Iain McInnes⁴, ¹Takeda Development Center Americas, Inc.,, Cambridge, MA, ²Takeda Development Center Americas, Inc., Cambridge, MA, ³Takeda Development Center Americas, Inc, Cambridge, MA, ⁴University of Glasgow, Glasgow, United Kingdom
Background/Purpose: There is a significant unmet need for clinically informative biomarkers of disease activity and therapeutic response in immune-mediated inflammatory diseases (IMIDs). Tyrosine kinase 2…
Abstract Number: 2372 • ACR Convergence 2025
Treatment Outcome and Persistence of IL-23 Inhibitors in Real World Cohort of PsA Patients- A Retrospective Study
Dana Rosenberg¹, Dafne capelusnik², Shai Shtrozberg³, Ori Elkayam⁴ and Reut Tzemach⁵, ¹Sourasky medical center Tel aviv ISRAEL, TEL AVIV, Israel, ²Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ³Sourasky medical center Tel aviv ISRAEL, TEL AVIV, ⁴Tel Aviv medical center, Tel Aviv, Israel, ⁵Sourasky medical center Tel aviv ISRAEL, Tel Aviv-Yafo, Israel
Background/Purpose: In recent years, IL-23 inhibitors (IL23i)-have emerged as promising therapeutic options for psoriatic arthritis patients (PsA). Clinical trials have demonstrated their efficacy in both…
Abstract Number: 0371 • ACR Convergence 2025
Lifestyle Coaching in Psoriatic Arthritis: Pilot Findings from an Online eCoaching Program
Judy Zhang¹, Leonard Calabrese², Shilpa Venkatachalam³, angela Degrassi⁴, Yuxuan Jin² and M. Elaine Husni⁵, ¹Cleveland Clinic, Cleveland, United States, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH, ³Global Healthy Living Foundation, New York, NY, ⁴Global Healthy Living Foundation, Upper Nyack, NY, ⁵Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH
Background/Purpose: As healthcare shifts towards patient-centered care, multifactorial lifestyle interventions, though effective, often impose time and resource burdens on patients. An online program like IMMUNE…
Abstract Number: 0546 • ACR Convergence 2025
Multimorbidity clusters in psoriatic arthritis, psoriasis, and axial spondyloarthritis and their association with healthcare utilization: A population-based study
Paras Karmacharya¹, Dilli Poudel², Daniel Shin³, Robert Fitzsimmons³, Leslie Crofford⁴ and Alexis Ogdie⁵, ¹Vanderbilt University, Nashville, TN, Hermitage, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³University of Pennsylvania, Philadelphia, ⁴Vanderbilt University Medical Center, Melbourne, AR, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Multimorbidity (≥ 2 chronic conditions) is common in inflammatory diseases such as psoriatic arthritis (PsA), psoriasis (PsO), and axial spondyloarthritis (AxSpA), increasing patient burden…
Abstract Number: 0566 • ACR Convergence 2025
Predictor Risk Factors For Developing Difficult-to-Treat Psoriatic Arthritis in Patients Initiating a First bDMARD: a Binational Study
Astrid Goudot¹, Raphaël Hurtubise², Eugénie Robin³, Laurine Cadart⁴, Raghav Ramachandran⁵, Federica Re⁵, Tristan Pascart⁶, Cécile Philippoteaux⁷, René-Marc Flipo⁷, Laura Coates⁸ and Jean-Guillaume Letarouilly¹, ¹Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, Lille, Nord-Pas-de-Calais, France, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Oxford, United Kingdom, ³CH Valenciennes, Service de rhumatologie, Valenciennes, France, Valenciennes, France, ⁴Service de biostatistiques, CHU Lille, Lille, France, Lille, France, ⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK, Oxford, United Kingdom, ⁶GHICL, Hôpital Saint-Philibert, Service de rhumatologie, Lomme, France, Lomme, France, ⁷Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, Lille, France, ⁸Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Risk factors to identify patients who will develop a difficult-to-treat (D2T) psoriatic arthritis (PsA) are still lacking when initiating a first bDMARD. There are…
Abstract Number: 0591 • ACR Convergence 2025
An Interim Analysis of Health-Related Quality of Life Outcomes from an International Multicentre Observational Study in Patients with Psoriatic Arthritis Initiating Bimekizumab in Real-World Clinical Practice
Xenofon Baraliakos¹, Uta Kiltz¹, Kurt de Vlam², Adeline Ruyssen-Witrand³, Felipe Julio Ramirez Garcia⁴, Jessica A. Walsh⁵, Denis Poddubnyy⁶, David Nicholls⁷, Marga Oortgiesen⁸, Francesca Maria Ester Castagna⁹, Marie-Alix Bonny¹⁰, Hervé Besson¹¹, Jérémy Lambert¹², Rajan Bajracharya¹³, Patrik Öhagen¹⁴ and William Tillett¹⁵, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²Department of Rheumatology, UZ Leuven, Leuven, Belgium, ³CHU of Toulouse - Pierre-Paul Riquet Hospital (Inflammation, Infection, Immunology and Locomotor Center - Rheumatology Service, Toulouse, France, ⁴Rheumatology Department, Hospital Clinic and IDIBAPS of Barcelona, Barcelona, Spain, ⁵Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁶Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ⁷Clinical Trials Unit, University of the Sunshine Coast, Queensland, Australia, ⁸UCB, Raleigh, NC, ⁹UCB SpA, Milano, Italy, ¹⁰UCB, Brussels, Belgium, ¹¹UCB, Breda, Netherlands, ¹²UCB, Colombes, France, ¹³UCB, Slough, England, United Kingdom, ¹⁴UCB, Stockholm, Sweden, ¹⁵Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom
Background/Purpose: PsA is a chronic inflammatory disease with a significant burden on patients’ (pts) health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal IgG1 antibody…
Abstract Number: 1414 • ACR Convergence 2025
Multidimensional Assessment to Differentiate Early Psoriatic Arthritis from Cutaneous Psoriasis
Eugeniu Russu¹, Victor Cazac², Mircea Betiu³, Alesea Nistor³ and Liliana Groppa⁴, ¹"Nicolae Testemitanu" State Medical and Pharmaceutical University; ”Timofei Moșneaga” Republican Clinical Hospital, Chisinau, Moldova, ²Norwalk Hospital, Nuvance Health, Connecticut, ³State Medical and Pharmaceutical University ”Nicolae Testemițanu”, Chisinau, Chisinau, Moldova, ⁴State Medical and Pharmaceutical University ”Nicolae Testemițanu”, Chisinau, Moldova
Background/Purpose: Psoriatic arthritis (PsA) develops in ~20-30% of psoriasis patients. However, early PsA diagnosis is challenging due to heterogeneous, subtle symptoms and overlap with psoriasis…
Abstract Number: 1454 • ACR Convergence 2025
Long-Term Safety and Tolerability of Bimekizumab Treatment Across Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update from the Phase 3 Studies
Philip J. Mease¹, Denis Poddubnyy², Rajan Bajracharya³, Barbara Ink³, Myriam Manente⁴, Luke Peterson⁵, Katy White⁶, Peter Nash⁷ and Lianne S. Gensler⁸, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ³UCB, Slough, England, United Kingdom, ⁴UCB, Braine-L'Alleud, Belgium, ⁵UCB, Morrisville, NC, ⁶UCB, Slough, United Kingdom, ⁷School of Medicine, Griffith University, Brisbane, Australia, ⁸Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA

Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. Previous analyses of phase (Ph)2b/3 safety data (data…

« Previous Page
1
…
5
6
7
8
9
…
93
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].